Core Viewpoint - INOVIO Pharmaceuticals is preparing for two major investor conferences in December to showcase its strategic initiatives and engage with investors [1][6] Group 1: Upcoming Conferences - The first conference is the Piper Sandler 37th Annual Healthcare Conference on December 2 in New York, where INOVIO will participate in a fireside chat available via live webcast [2] - The second event is the Oppenheimer Movers in Rare Disease Summit on December 11, where INOVIO will join a panel discussing key near-term catalysts [3] Group 2: Stock Performance - INOVIO's stock price was $1.95 at the time of the Piper Sandler announcement but has decreased to $1.79, reflecting a 5.29% decline [2][3] - The stock has fluctuated between $1.78 and $1.90 on the day of reporting, with a market capitalization of approximately $95.93 million [4] - Over the past year, INOVIO's stock reached a high of $4.61 and a low of $1.30, with a trading volume of 1,073,702 shares on NASDAQ [5]

Immutep (NasdaqGM:IMMP) 2025 Conference November 19, 2025 05:00 PM ET Speaker1Very good. We're going to have a bit of a fireside discussion today, which I'm very much looking forward to. Before I get to some questions, I'll just provide a brief introduction for our audience. Immutep is a clinical stage company with its lead drug candidate in phase three clinical trials for lung cancer, as well as having a second asset undergoing trials for an autoimmune condition. Under Mark's leadership, Immutep has reache ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. So what: If you purchased Skye s ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema f ...

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs’ rights firm Hagens Berman has been investigating the alleged claims. The firm urges investors in aTyr who suffered significant losses to submit your losses now. ...

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 19, 2025 3:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 19, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates i ...

Financial Data and Key Metrics Changes - The company has a market cap of approximately $12 million, with stock trading around $0.25 to $0.30 per share, reflecting a significant decline from previous levels [32][56]. - The company is estimating to collect at least $50 million net from Crown Medical's initiatives, which is expected to significantly improve the financial structure [17][18]. Business Line Data and Key Metrics Changes - Crown Medical Collections has been appointed as special counsel to pursue approximately $150 million in uncollected COVID testing claims, with expectations of settlements starting soon [10][15]. - The B-Smart esophageal cancer test is positioned as a potentially multi-billion dollar market opportunity, with a target market estimated between $7 billion and $14 billion [21][22]. Market Data and Key Metrics Changes - The company is experiencing a disconnect between its market cap and the underlying asset value, particularly with the anticipated cash inflow from Crown Medical [7][17]. - The company has not utilized its ATM (at-the-market) facility yet, indicating a cautious approach to financing amid current market conditions [18]. Company Strategy and Development Direction - The company is focusing on strategic initiatives that could recognize significant underlying value, including a potential reverse stock split and a crypto treasury strategy [5][37]. - The management is committed to maintaining NASDAQ compliance to facilitate potential strategic deals and enhance shareholder value [37][52]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges but expresses optimism about upcoming cash flows from Crown Medical, which could transform the company's financial position [28][59]. - The management emphasizes the importance of shareholder voting to support strategic initiatives and maintain compliance with NASDAQ [38][52]. Other Important Information - The company has undergone significant restructuring, including the sale of its Farm Labs manufacturing facility and the shutdown of its Nebula Genomics laboratory, to streamline operations and reduce overhead [27]. - Management has deferred salaries to support the company financially, indicating a commitment to the company's success [31]. Q&A Session Summary Question: Clarification on potential major deals - Management is exploring multiple strategic deals, including a reverse crypto strategy and other initiatives that could enhance shareholder value [40]. Question: Impact of reverse stock split on stock price - Management believes that a reverse stock split could potentially lead to an increase in stock price, especially if the company maintains its underlying asset value [42][44]. Question: Plans for employee compensation amid cash constraints - Management reassures that there are multiple funding options available, including debt, to support operations and employee compensation [46]. Question: Strategy for B-Smart esophageal cancer test funding - Management intends to leverage cash flow from Crown Medical to fund the B-Smart initiative, with potential for joint ventures to enhance value [60][62]. Question: Addressing ongoing stock price decline - Management attributes the stock price decline to market conditions and short selling, expressing confidence that cash flow from Crown Medical will drive stock price recovery [58].

PresentationOperator Hello, and welcome to the Protara Update Call. We ask that you please hold all questions until the completion of the formal remarks at which time you will be given instructions for the question-and-answer session. Also, as a reminder, this conference is being recorded. If you have any objections, please disconnect at this time. With that, I would now like to turn the call over to Justine O'Malley, Senior Vice President, Investor Relations and Corporate Affairs. ...

Question-and-Answer SessionDouglas SchenkelWolfe Research, LLC So in terms of the framework for this morning, I wanted to quickly maybe start by talking about the state of the company, how things have continued to evolve under your leadership. The second thing is I really want to focus on unpacking some of the new disclosures from Q3 on the clinical side. So I do want to spend a few minutes on how we should be thinking about the clinical transition. Third, it's kind of a hodgepodge of recent development que ...